Zensar Technologies Ltd DCF Valuation and Stock Price Analysis July 2026

Zumedha Insights
Research . Analysis . Insights
ACCUMULATE
CMP₹431.80
(as on 01 Jul 2026)

Zensar Technologies Ltd

Digital Engineering & Experience-Led IT Services — RPG Group
NSE
ZENSARTECH
BSE
504067
ISIN
INE520A01027
Face Value
₹2.00
52W High/Low
₹881 / ₹424
Market Cap
₹9,644 Cr
Shares O/S
22.75 Cr
Promoter Holding
49.01%
CMP
₹431.80
Mkt Cap
₹9,644 Cr
52W H/L
₹881/₹424
P/E
12.7x
Revenue FY26
₹5,687 Cr
PAT FY26
₹775 Cr
EBITDA Margin
16.1%
Section 01

Business Overview

Zensar Technologies is a Pune-headquartered, mid-sized digital engineering and IT services company, part of the Mumbai-based RPG Group (Harsh Goenka, Chairman). Incorporated in 1963 and rebranded in 2021 around an “experience-led everything” strategy, Zensar today serves 178+ active clients across Banking, Financial Services & Insurance (BFSI), Hi-Tech & Manufacturing, Consumer Services, Healthcare & Life Sciences, and Utilities, with a workforce of over 10,700 professionals across 30+ global locations (India, USA, UK, Europe, South Africa).

The company operates through two reporting segments — Application Management Services (AMS) and Infrastructure Management Services (IMS) — with digital and application services (testing, modernization, cloud-native application development, data engineering, AI/GenAI, and enterprise platforms such as Oracle, Salesforce and SAP) contributing the bulk of revenue. Zensar has been actively investing in agentic AI and GenAI-led delivery, cloud (notably a new AWS Data & Analytics Competency), and has bolstered its US life-sciences presence via the FY25 acquisition of BridgeView Life Sciences.

Incorporated
1963
Active Clients
178+
Employees
10,700+
Promoter Group
RPG
Section 02

Historical Financials

Zensar’s revenue has compounded at a modest 9% CAGR over 5 years (8% TTM), but profitability has scaled meaningfully faster — 19% PAT CAGR over 5 years and 27% over 3 years — aided by margin discipline, tax efficiency and other income from a growing treasury book.

₹ Cr (Consolidated)FY22FY23FY24FY25FY26
Revenue4,2444,8484,9025,2815,687
Operating Profit (EBITDA)656552872817916
OPM %15%11%18%15%16%
PBT5744448768581,022
Net Profit422328665650775
EPS (₹)18.4014.4729.3428.6134.05
Free Cash Flow279681627530719
FY26 (Q4): Net profit rose 19.4% YoY to ₹210.6 Cr on revenue of ₹1,450.4 Cr (+6.7% YoY); order book surged to $401.8M. Board declared its highest-ever dividend of ₹12.6/share, payout ~37% of FY26 profit. Balance sheet remains near debt-free (borrowings of just ₹79 Cr against reserves of ₹4,674 Cr), with ROE of 18% and ROCE of 24%.
Section 03

DCF Valuation

A 10-year discounted free cash flow model, using FY26 normalised FCF of ₹719 Cr as the base, tapering growth from 10% (Years 1–3) to 8% (Years 4–6) to 6% (Years 7–10), a WACC of 12% and terminal growth of 5%, points to meaningful intrinsic value headroom over the current market price.

DCF ASSUMPTIONS & OUTPUT
WACC
12.0%
Terminal Growth
5.0%
Base FCF (FY26)
₹719 Cr
PV of 10-Yr FCF
₹6,114 Cr
PV of Terminal Value
₹7,351 Cr
Enterprise Value
₹13,465 Cr
Net Cash Adj.
+₹1,842 Cr
Equity Value
₹15,307 Cr
DCF Value / Share
₹673

At ₹673/share, the DCF fair value implies ~56% upside to CMP — broadly corroborated by Motilal Oswal’s independently derived target of ₹640 (31% upside), suggesting the market is pricing in more conservative growth/margin assumptions than the model above.

Section 04

Relative Valuation & Peer Multiples

Zensar trades at a steep discount to the broader IT services peer set — a function of its smaller scale, historically slower revenue growth and elevated working-capital days — but also reflects a much lower starting valuation base, offering re-rating potential if execution stays consistent.

CompanyP/E (x)P/B (x)ROE %Rev. Growth %
Zensar Technologies12.72.118.18.0
Persistent Systems45.012.524.018.0
Coforge38.010.022.025.0
Mastek18.03.215.07.0
Cyient19.02.412.03.0
IT Sector (broad)~20.0———

Applying a conservative re-rated multiple of 15x–18x to FY26 EPS of ₹34.05 (below peer average, given Zensar’s smaller size and single-digit growth profile) yields a fair value band of roughly ₹511–₹613 per share, consistent with the DCF-implied upside.

Section 05

Asset-Based Valuation (NAV)

As an asset-light IT services business, book value is a conservative valuation floor rather than a primary anchor. Consolidated net worth stood at ₹4,719 Cr (equity capital ₹45 Cr + reserves ₹4,674 Cr) as of Mar-2026, translating to a book value of ~₹207/share. The company holds ₹1,921 Cr of investments (largely treasury/liquid funds) against just ₹79 Cr of borrowings — a strong net-cash position that provides valuation and balance-sheet downside protection.

Book Value/Share
₹207
P/B (CMP)
2.1x
Net Cash
₹1,842 Cr
Debt/Equity
0.02x
Section 06

Earnings Power Value (EPV)

EPV strips out growth assumptions and capitalises normalised, sustainable NOPAT at the cost of capital — a useful “no-growth floor” for the business. Using FY26 operating profit of ₹916 Cr, normalised at a 24% effective tax rate (NOPAT ≈ ₹696 Cr) and capitalised at 12% WACC, EPV works out to approximately ₹5,800 Cr, or roughly ₹255/share — below CMP, as expected, since EPV excludes the growth optionality from AI-led deals and margin expansion that DCF and relative valuation both credit.

EPV of ₹255/share versus CMP of ₹431.80 confirms the market is already pricing in some growth; the gap to DCF (₹673) is where the incremental re-rating opportunity lies, contingent on Zensar sustaining double-digit order-book growth and 16%+ EBITDA margins.
Section 07

Sum-of-the-Parts (SOTP)

Zensar operates as a largely integrated digital services business rather than a multi-vertical conglomerate, so SOTP is applied conservatively across its two reporting lines.

SegmentApprox. Revenue MixApplied Multiple (EV/EBITDA)Implied Value (₹ Cr)
Application Management & Digital Services~82%10.5x7,890
Infrastructure Management Services~18%7.0x1,155
Total Enterprise Value100%—9,045

Adding net cash of ₹1,842 Cr to the SOTP-derived enterprise value of ~₹9,045 Cr gives an equity value of ~₹10,887 Cr, or approximately ₹479/share — positioned between the EPV floor and DCF/relative valuation ceiling, reinforcing the case that CMP sits below intrinsic value on most methodologies.

Section 08

Buy Range

Strong Buy
Below ₹390
Deep value zone — largest margin of safety versus EPV/SOTP floor; typically coincides with sector-wide IT sell-offs.
Accumulate
₹390 – ₹450
Current CMP (₹431.80) sits in this zone — favourable risk-reward with meaningful gap to DCF/relative fair value.
Fair Value
₹450 – ₹520
Approaches SOTP/relative valuation midpoint; incremental buying should be more selective here.
Section 09

Buy Scenario

Bear Case
₹380

Order-book momentum stalls, margins compress toward 14-15% amid pricing pressure and BFSI/Hi-Tech demand softness.

Base Case
₹560

Steady 8-10% revenue growth, EBITDA margin holds near 16%, AI/GenAI deal wins offset legacy AMS pricing pressure.

Bull Case
₹700+

Large deal wins accelerate (order book already +122.9% QoQ), margin expansion to FY27 guided 16.1%+, multiple re-rates toward mid-cap IT peers.

Section 10

Sell Range

Reduce
₹580 – ₹650
Approaches DCF fair value and Motilal Oswal target (₹640); consider trimming positions built at lower levels.
Exit
₹650 – ₹720
Valuation stretches beyond most intrinsic-value estimates without a corresponding step-up in growth/margin profile.
Avoid Fresh Buying
Above ₹720
Nearing 52-week high territory (₹881); risk-reward turns unfavourable for new capital at these levels.
Section 11

Sell Scenario

Overvalued
₹650+

Price runs materially ahead of DCF/relative fair value without earnings upgrades to justify the re-rating.

Exit Trigger
Margin <14%

Sustained EBITDA margin compression below 14% for 2+ quarters, or client concentration/attrition shocks.

Structural Break
Growth <3%

Multi-year revenue growth falling below 3% CAGR would signal structural share loss to larger peers — reassess thesis entirely.

Section 12

Future Growth Drivers

Management guidance points to FY27 EBITDA margin of ~16.1%, supported by an AI-led strategy emphasising large deal wins and sector-focused go-to-market. The order book surged 122.9% QoQ to $401.8M exiting FY26 — the strongest forward indicator in several years — while the recent AWS Data & Analytics Competency certification and BridgeView Life Sciences acquisition extend Zensar’s addressable market in cloud/data and US healthcare respectively. Active client additions (+7.2% YoY to 178) and improving net profit margins (13.5%, +120bps YoY) both point to a business scaling more profitably even as top-line growth stays moderate.

Key watch item: working capital days have risen sharply from 61 to 126 over recent years — a trend that needs to reverse for free cash flow conversion to keep pace with reported profit growth.
Section 13

Risks & Catalysts

Catalysts

  • 122.9% QoQ order-book surge signals accelerating revenue visibility into FY27
  • Near debt-free balance sheet with ₹1,842 Cr net cash cushions margin volatility
  • Highest-ever dividend (₹12.6/share) signals management confidence in cash generation
  • AI/GenAI-led deal positioning and AWS Data & Analytics Competency open new revenue pools
  • Valuation discount to peers (12.7x vs ~20x sector) leaves room for re-rating on consistent execution

Risks

  • Five-year revenue CAGR of just 8.5% — among the slowest in the mid-cap IT peer set
  • Working capital days have more than doubled (61 → 126), pressuring cash conversion
  • Client/vertical concentration risk in BFSI and Hi-Tech & Manufacturing amid global demand uncertainty
  • Stock down ~33-48% over the past year — reflects sector de-rating that could persist if IT spending stays soft
  • Currency/geopolitical exposure given large US/UK/Europe revenue base
Verdict

Weighing DCF (₹673), relative valuation (₹511–613), SOTP (~₹479) against the EPV floor (₹255) and current CMP of ₹431.80, this analysis suggests Zensar Technologies offers a favourable risk-reward at current levels for investors comfortable with the mid-cap IT services growth profile. The company’s near debt-free balance sheet, improving margins, and a sharply rebuilt order book provide reasonable downside protection, while the valuation gap versus peers and DCF fair value offers meaningful re-rating potential should execution stay on track. This analysis suggests a staggered accumulation approach in the ₹390–450 band, with a recommended investment horizon of 18–24 months, allowing the FY27 order-book conversion and margin trajectory to play out.

Disclaimer: This report is prepared by Zumedha Insights for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All data is sourced from publicly available filings, exchange disclosures and third-party financial platforms believed to be reliable as of the date of publication, but accuracy and completeness are not guaranteed. Equity investments are subject to market risk; past performance is not indicative of future results. Readers should conduct their own due diligence or consult a SEBI-registered investment advisor before making investment decisions. Zumedha Insights and its analysts may or may not hold positions in the securities discussed.

Hot this week

HDFC Bank Technical Analysis November 2026

HDFC Bank closed at ₹788.25 on 6 Nov 2026, up about 17.8% from its 52-week low. This technical analysis covers moving averages, RSI, MACD, pivots, Fibonacci levels, volume and scenarios using cross-checked data

What Is Fundamental Analysis of a Stock? Complete Guide with Example

Fundamental analysis estimates what a company's shares are truly worth by studying its business, financial statements and growth outlook. This guide covers the key ratios, valuation methods and a step-by-step worked example

Aster DM Quality Care (ASTERDM) stock Analysis November 2026

Aster DM Quality Care’s merger with Quality Care India created a 39-hospital, ~10,600-bed platform. This analysis weighs five valuation methods, news and sentiment to estimate a fair value of ₹514 against a CMP of ₹719.55

Asian Paints Share Price Target, Fundamental & Technical Analysis November 2026

Asian Paints (NSE: ASIANPAINT) fundamental and technical analysis after Q2 FY27: five valuation methods, a weighted fair value of ₹1,493 against a CMP of ₹2,523.80, buy and sell ranges, risks, and key support and resistance levels

Marico Ltd (NSE: MARICO) Share Price Target 2026: Stock Analysis & Fair Value

Marico's Q2 FY27 brought 10% India volume growth, 27% EBITDA growth and raised FY27 guidance. This Zumedha analysis values the stock with DCF, peer multiples, NAV, EPV and SOTP, and arrives at a Weighted Fair Value of ₹583 against a CMP of ₹878, with buy and sell ranges, scenarios and risks

Topics

Indian Hotels DCF Valuation & Share Price Analysis Aug 2026

.zumedha-report{ --ink:#1a1208; --paper:#faf7f2; --cream:#f2ede4; --red:#c8381e; --gold:#b8860b; --green:#1a6b3a;...

YES Bank DCF Value Analysis March 2026

YES Bank — Deep Analysis Report:root { ...

Control Print Limited Share Price Analysis April 2026

Control Print Limited — Deep Value Analysis@import...

CG Power Share Price Target | CGPOWER Stock Analysis & DCF Valuation Sep 2026

.zumedha-report{ --ink:#1a1208; --paper:#faf7f2; --cream:#f2ede4; --red:#c8381e; --gold:#b8860b; --green:#1a6b3a; --blue:#1a3f6b;...

Axis Bank Share DCF Value Analysis April 2026

@import url('https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;600;700&family=Source+Serif+4:wght@300;400;600&family=IM+Fell+English+SC&family=JetBrains+Mono:wght@400;500;600&display=swap');.zumedha-report-axis * { box-sizing: border-box; margin:...

HDFC Bank Technical Analysis November 2026

HDFC Bank closed at ₹788.25 on 6 Nov 2026, up about 17.8% from its 52-week low. This technical analysis covers moving averages, RSI, MACD, pivots, Fibonacci levels, volume and scenarios using cross-checked data

HDFC Bank (NSE: HDFCBANK) — Stock Analysis April 2026

HDFC Bank — Equity Research Report:root { ...

Tata Capital Share Price Analysis April 2026

Tata Capital — Zumedha Insights:root { ...

Related Articles